Previous clinical studies have validated the potential of VGT-309, and these additional funds will enable us to efficiently advance our current and future clinical trials in #LungCancer.

We are grateful to the NCI and the team at Penn for their support of our Phase 2 trial of VGT-309 in lung cancer.

It was great to have so many attendees at Dr. Wright's presentation of phase 2 VGT-309 study data earlier today. #WCLC23 IASLC

The VISUALIZE study is an exciting next step for VGT-309 and we look forward to further evaluating its utility in lung cancer surgery.